BiomX Inc. — Director's Dealing 2023

Dec 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BiomX Inc. (PHGE)
CIK: 0001739174
Period of Report: 2023-12-11

Reporting Person: Solomon Jonathan Eitan (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-11	Common Stock Options - Right to Buy	$6.21	D	144000	Disposed	2030-03-25	Common Stock (144000)	Direct
2023-12-11	Common Stock Options - Right to Buy	$0.2749	A	37895	Acquired	2030-03-25	Common Stock (37895)	Direct
2023-12-11	Common Stock Options - Right to Buy	$7.02	D	152000	Disposed	2031-03-30	Common Stock (152000)	Direct
2023-12-11	Common Stock Options - Right to Buy	$0.2749	A	40000	Acquired	2031-03-30	Common Stock (40000)	Direct
2023-12-11	Common Stock Options - Right to Buy	$1.41	D	205000	Disposed	2032-03-29	Common Stock (205000)	Direct
2023-12-11	Common Stock Options - Right to Buy	$0.2749	A	146429	Acquired	2032-03-29	Common Stock (146429)	Direct

Footnotes

F1: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.

F2: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

F3: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.

F4: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

F5: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 205,000 shares of the Issuer's common stock granted to the Reporting Person on March 29, 2022. In exchange, the Reporting Person received a replacement option, for 146,429 shares, having an exercise price of $0.2749 per share.

F6: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 29, 2023, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.